FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

AARTIDRUGS Consensus Forecast

No. of reports in last year
1
No. of analysts
1
Average Consensus Forecast
796
Consensus Potential
-118.62%

AARTIDRUGS Price Target Potential

BrokerageTargetPotential

AARTIDRUGS Targets in FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for AARTIDRUGS
0% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

AARTIDRUGS Ratings

Long term AARTIDRUGS rating by FrontPage users
5/5 (1 Ratings)

1 AARTIDRUGS share price target reports by brokerages below. See what is analyst's view on AARTIDRUGS share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. AARTIDRUGS Forum
  3. AARTIDRUGS Price Target

AARTIDRUGS Share Price Target

AARTIDRUGS Share Price Target - Broker Reports - 2019

18-Jun-19
Price @ Call: 522.45
Target: 796
BUY
We recently met the management of Aarti Drugs to discuss its expansion plans, past obstacles and the path forward. With added capacities in a few of its therapies, we expect its revenue/PAT to clock 14.5%/32% CAGRs over FY19-21. We maintain our Buy rating, with an unchanged target of Rs 796.
... Read more

AARTIDRUGS Share Price Target - Broker Reports - 2018

4-Oct-18
Price @ Call: 564
Target: 910
BUY
We maintain our Buy rating on Aarti Drugs (ADL) and retain the TP to Rs910 based on 16x March’20 EPS of Rs56.8. ADL is the market leader in 9 out of 10 APIs manufactured by the company. That said, the company is likely to benefit from vertical integration which is likely to drive future growth. We expect margins to improve post the launch of new products and additional capacities of Ciprofloxacin and Metformin APIs in place. Key risks to our assumptions include slowdown in the domestic pharma market and regulatory risks for its manufacturing facilities.
... Read more
14-Jun-18
Price @ Call: 534.3
Target: 720
BUY
15-Jan-18
Price @ Call: 755
Target: 940
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • AARTIDRUGS Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 31,851.47
    Upside Target 21,822.73
    Upside Target 11,784.87
    Pivot1,756.13
    Downside Target 11,718.27
    Downside Target 21,689.53
    Downside Target 31,651.67
  • AARTIDRUGS Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 31,992.03
    Upside Target 21,898.52
    Upside Target 11,819.38
    Pivot1,725.87
    Downside Target 11,646.73
    Downside Target 21,553.22
    Downside Target 31,474.08
  • AARTIDRUGS Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 32,515.17
    Upside Target 22,160.08
    Upside Target 11,950.17
    Pivot1,595.08
    Downside Target 11,385.17
    Downside Target 21,030.08
    Downside Target 3820.17
  • AARTIDRUGS Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 31,822.73
    Upside Target 21,797.29
    Upside Target 11,781.57
    Pivot1,756.13
    Downside Target 11,730.69
    Downside Target 21,714.97
    Downside Target 31,689.53
  • AARTIDRUGS Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 31,898.52
    Upside Target 21,832.56
    Upside Target 11,791.82
    Pivot1,725.87
    Downside Target 11,659.91
    Downside Target 21,619.17
    Downside Target 31,553.22
  • AARTIDRUGS Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 32,160.08
    Upside Target 21,944.25
    Upside Target 11,810.91
    Pivot1,595.08
    Downside Target 11,379.25
    Downside Target 21,245.91
    Downside Target 31,030.08
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020